- Business
- Bombay Super Hybrid Seeds Limited engages in the production, processing, and marketing of hybrid and genetically modified seeds for field crops and vegetables; its core products encompass over 150 varieties including groundnut, onion, coriander, cumin, rajka bajri, chickpea, wheat, sesame, maize, soybean, black gram, green gram, limabean, pigeon pea, peas, cowpea, fenugreek, mustard, drumstick, gum guar, lucerne, papaya, watermelon, muskmelon, isabgol, lentil, and hybrid sweet corn, marketed under the Bombay Super and Kasturi brands to farmers across India and for export; the company operates an 85,000 sq.ft ultra-modern seed processing unit in Rajkot, Gujarat, and maintains ISO 9001:2015 certification with seeds certified by the Gujarat State Seed Certification Agency for high yield, disease resistance, and organic cultivation suitability. Founded in 1983 by Patel Jadavjibhai Devrajbhai as a bulk seed business and formally incorporated in 2014 with headquarters at Plot No. 11, Shreenathji Industrial Estate, near Kuvadva GIDC, National Highway 8B, Rajkot, Gujarat, India, the company expanded under Managing Director Arvindkumar Kakadiya (Pintu Patel) from 2005 by establishing its own brand, developing R&D ties with Junagadh Agricultural University, and building a marketing network across Gujarat and seven key agricultural states while focusing on edible oilseeds like groundnut and sesame. Recent developments include publication of unaudited Q1 FY2026 financial results on July 31, 2025, in compliance with SEBI regulations showing trailing twelve-month revenue of INR 3.55 billion and net income of INR 275.52 million; the 11th Annual General Meeting on August 6, 2025, approving financial statements, director reappointments, related party transactions, and auditors; trading window closure on September 26, 2025, ahead of Q2/H1 FY2026 results; and strategic R&D collaborations with ICAR, SAUs, CIMMYT, IRRI, ICRISAT for crop-specific improvements in groundnut, rice, vegetables, and wheat, alongside adoption of genomics, bioinformatics, and CRISPR/Cas9 technologies, with strong revenue growth of 28% CAGR over 10 years and profit growth of 58.2% CAGR over five years.